Other Clinical Trial - A Study to Evaluate Safety & Tolerability of a

See also
Status	Clinical Trial	Phase
Completed	`NCT04926194` - Decidual Stromal Cells to Treat Graft-vs-Host Disease After Stem Cell Transplant for Myelodysplastic Syndrome/Myeloproliferative Neoplasm	Phase 2
Recruiting	`NCT04554914` - A Study to Evaluate Tabelecleucel in Participants With Epstein-barr Virus-associated Diseases	Phase 2
Recruiting	`NCT03394365` - Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy	Phase 3

See also

Status

Clinical Trial

Phase

Completed

NCT04926194 - Decidual Stromal Cells to Treat Graft-vs-Host Disease After Stem Cell Transplant for Myelodysplastic Syndrome/Myeloproliferative Neoplasm

Phase 2

Recruiting

NCT04554914 - A Study to Evaluate Tabelecleucel in Participants With Epstein-barr Virus-associated Diseases

Phase 2

Recruiting

NCT03394365 - Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy

Phase 3

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT01903928
Study type	Interventional
Source	Astellas Pharma Inc
Contact
Status	Completed
Phase	Phase 2
Start date	June 20, 2013
Completion date	January 19, 2015

A Study to Evaluate Safety and Tolerability of a Therapeutic Vaccine, ASP0113, in Subjects Undergoing Allogeneic Hematopoietic Cell Transplant

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms